Initial findings from a phase 2b clinical trial demonstrate the safety and efficacy of three different daily doses of SAP-001 to lower the serum urate levels of patients with refractory gout.
Gout Resource Center
Earlier this year, the ACR released a new guideline for the management of gout, leaving some rheumatologists unsure what to recommend to their patients. Clearing up the confusion is one aim of the session, Evidence-Based Guidance for Optimizing Gout Management. Learn what the experts recommend and explore our coverage of additional gout information presented at ACR Convergence 2020, plus our collection of research reviews, case reports and clinical articles on advances in the diagnosis and management of gout.
VIEW
FDA Approves Oral Solution of Colchicine to Prevent Gout Flare
The FDA approved an oral solution of colchicine for the prevention of gout flare in adults. Its dosage can be easily adjusted on the basis of patient needs.
A ‘Polarized’ Topic: Synovial Fluid Crystal Examinations
Answer a short survey to help the ACR’s Committee on Rheumatologic Care decide whether the ACR should seek CMS approval for synovial fluid crystal analysis as a provider-performed microscopy procedure.
Sunrise, Sunset: A Look Back on the Year in Rheumatology
At the ACR Convergence 2024 Year in Review lecture, experts discussed advancements in disease understanding and treatments, as well as in basic science.
Urate-Lowering Therapy in the Treatment of Patients with Chronic Kidney Disease
In a new-patient consultation for joint pain, you see a 75-year-old man with a history of dementia, stage 3a chronic kidney disease (CKD) and nephrolithiasis. He has a uric acid level of 7.5 mg/dL. His medication list includes 300 mg daily allopurinol. What is NOT an indication for allopurinol? CKD-FIX Elevated serum urate levels are…
Top Research in Gout from ACR Convergence 2024 at a Glance
Dr. Lisa Stamp helps filter the noise to get to the key insights from the research abstracts on gout presented at ACR Convergence 2024.
Better Education on Gout
Experts addressed how education and follow-up for patients with gout can improve disease management and highlighted the need for a better construction of gout remission.
Lubricin/CD44/PP2A Pathway Offers New Therapeutic Targets for Patients with Gout
Dr. Khaled Elsaid discussed synovial macrophages/monocytes and monosodium urate crystal interactions at a session during ACR Convergence, exploring potential new gout pharmacology targets via the lubricin/CD44/protein phosphatase 2A (PP2A) pathway.
Progress in Gout Education & Remission
An ACR Convergence 2024 session will discuss strategies to educate patients about their disease and review the progress toward the concept of remission in gout to better guide physicians.
Novel Mechanisms of Gout Explored
In a session at ACR Convergence 2024, expert panelists with go into depth concerning molecular mechanisms that contribute to gout pathogenesis.
- 1
- 2
- 3
- …
- 21
- Next Page »